Jeff Gundlach, CEO of DoubleLine Capital, criticized NVIDIA Corporation (NVDA.US) for signing memorandums of understanding with six major financial institutions to raise more than USD500 billion for AI infrastructure, opining Wall Street is trying to turn AI chips into an investable asset class, which could signal that risk markets are approaching a peak.

Gundlach questioned whether it is wise to use rapidly evolving technology as collateral for long-term borrowing. He believed NVIDIA's fundraising plan is unlikely to stand the test of time, comparing the situation to using a warehouse full of bananas as collateral for 30-year asset-backed securities, even if those bananas are newly cultivated bananas with unknown longevity.
~

AASTOCKS Financial News
Website: www.aastocks.com

Even if AI development ultimately meets investors' expectations, US tech stocks could still undergo a correction, potentially threatening financial stability in the euro area, European Central Bank (ECB) economists said in a blog post.

A correction in the tech sector would not necessarily be caused by previous investor hype, and such a pullback would still be expected even if current valuations are at reasonable levels.

The economists noted that households in the euro area have around EUR440 billion of exposure to US tech stocks, mainly through investment funds, while insurance companies and pension funds also have significant exposure to the "Magnificent 7".
~

AASTOCKS Financial News
Website: www.aastocks.com

SINGAPORE, Aug. 18, 2026 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, today announced that its BCM3 dual-function production line for antibody intermediates and drug substances of bioconjugates at Singapore site has successfully achieved GMP release. This milestone marks a new phase in the company's global capacity expansion, empowering clients worldwide to accelerate commercial manufacturing with greater efficiency and flexibility in meeting diverse demands.

As the company's first overseas GMP-released facility, BCM3 features an efficient and flexible "dual-function" design, offering integrated end-to-end commercial manufacturing services from antibody intermediates to conjugated drug substances. The production line supports batch sizes from 200 L to 2,000 L for antibody intermediates and up to 2,000 L for conjugated drug substances, fully meeting commercial-scale requirements while adhering to a rigorous quality control system. As a critical component of WuXi XDC's global manufacturing network, BCM3 will work in synergy with the BCM1 and BCM2 lines at the Wuxi site, substantially boosting overall capacity for both antibody intermediates and conjugated drug substances.

During the construction process, WuXi XDC leveraged its proven facility construction expertise from the Wuxi site while adapting to local conditions in Singapore, successfully delivering high-standard cleanroom areas and supporting utility systems. Notably, the team overcame significant challenges in the design and construction of high-potency, high-toxicity manufacturing zones. The flexible multi-purpose layout enables BCM3 to accommodate different projects, while optimized internal flow design has markedly reduced the time for material transfer and waiting, improving overall manufacturing efficiency. From facility design to GMP release, the entire process was completed in just two and a half years, once again demonstrating the exceptional "WuXi Speed."

Dr. Jimmy Li, CEO of WuXi XDC, commented: "The successful GMP release of our first overseas facility is a major milestone for WuXi XDC's global manufacturing strategy. We are honored to receive congratulations from clients worldwide on this GMP release. With the synergistic 'China + Singapore' dual-site advantage, we will not only significantly enhance our agility in responding to diverse orders but also provide our clients with a robust capacity foundation for commercial manufacturing. Looking ahead, WuXi XDC will continue to deliver high-quality, integrated services that create value for global clients and drive the high-quality growth of the bioconjugate industry."

Reflecting on the journey of building the Singapore site, it is the collective efforts and relentless perseverance of the team that have seen us through every challenge—showcasing WuXi XDC's outstanding execution and steadfast commitment to accountability. Since the Singapore site announcement in March 2024, mechanical completion in June 2025, followed by commissioning and qualification (C&Q), and now the GMP release of BCM3, WuXi XDC has steadily executed the entire journey from blueprint to operational readiness, fulfilling its international capacity commitments. According to the subsequent plan for the Singapore facility, the DP4 (drug product filling line) is scheduled to achieve GMP release by the end of August 2026. As the "Global Dual-Sourcing" strategy continues to mature, the Singapore and Wuxi sites will integrate and collaborate more deeply, building a comprehensive, multi-dimensional network that combines global service with local responsiveness.

About WuXi XDC

WuXi XDC Cayman Inc. (stock code: 2268.HK) is a globally recognized contract research, development, and manufacturing organization (CRDMO) specializing in bioconjugates. The company offers a wide range of innovative conjugation and payload-linker technologies to facilitate the development of next-generation antibody-drug conjugates (ADCs). Focused on early-stage research and development of ADCs and other bioconjugates, WuXi XDC offers comprehensive one-stop services from clinical to commercial manufacturing. Its services cover antibody intermediates and other biologics intermediates, chemical payloads and linkers, as well as bioconjugate drug substances and drug products. For more information about WuXi XDC, please visit: www.wuxixdc.com

WuXi XDC Contacts

Investor: [email protected] 
Media: [email protected] 
BD: [email protected] 

新加坡和上海2026年8月18日 /美通社/ -- World Group Limited（納斯達克股票代碼：HTHT；香港交易所股票代碼：1179）作為全球領先的酒店集團之一，今日公佈了 2026 年第二季度的未經審計財務業績，展現出強勁的盈利能力，其輕資產業務持續改善，並再次交出穩健的季度表現。

截至 2026 年 6 月 30 日，該集團營運 13,539 間酒店，共計 1,335,445 間客房，並有 3,089 間酒店正在籌建中。

本季度，酒店交易總額達到 305 億元人民幣，較去年同期增長 13.2%。 

H World 行政總裁金輝表示：「在第二季，我們再次實現了每間可出租客房收入 (RevPAR) 的增長。H World 中國區的綜合平均房價 (ADR) 年增 2.6%，帶動綜合 RevPAR 年增 1.1%。這表現得益於持續進行的產品升級，以及一系列收益管理優化措施。與此同時，我們的酒店網絡持續穩健擴張，全中國新開業酒店達 498 間；而開發中的酒店數量，無論是與去年同期相比，還是與上季相比，均有所增長。我們仍穩步朝著實現全年總開業目標 2,200 至 2,300 間酒店的指引邁進。」

強勁的財務表現

H World 於第二季交出了亮眼的財務表現，收入年增 10.8%，達 71 億元人民幣。經調整後 EBITDA 總額年增 20.0%，達 27 億元人民幣。

管理加盟及特許經營 (「M&F」) 業務的營收較去年同期增長25.2%，達 36 億人民幣。M&F 業務收入較去年同期增長 25.2%，達 36 億人民幣。M&F業務的營業毛利增長 18.5%，達 22 億人民幣，反映本集團「輕資產」營運策略持續取得進展。

加速股東回報

該集團已提前完成於 2024 年宣佈的 20 億美元股東回報計劃，彰顯出其強勁的現金生成能力及穩健的資產負債表。

基於這項進展，董事局已批准一項為期三年、總額為 25 億美元的新股東回報計劃，該計劃自 2026 年 8 月 17 日起生效，將透過現金股息及股份回購實施。

展望未來，H World 將持續致力於推動「品牌主導」的高品質飯店網絡擴張，並以 H Rewards 會員計劃、技術發展及進一步提升營運效率為後盾。

針對 2026 年全年，H World 將收入成長的預測上調至 4% 至 8% 之間。

如欲查看完整新聞稿，請瀏覽：

https://ir.hworld.com/news-releases/news-release-details/h-world-group-limited-reports-second-quarter-and-interim-2026

H World Group Limited 簡介

H World Group Limited 總部位於中國（納斯達克股票交易所代號：HTHT；香港交易所股票代碼：01179) 是全球酒店行業的重要參與者。過去 20 年來，H World 已發展成為領先的酒店集團，業務遍及從經濟型到中高檔及生活風格酒店等多元市場領域。H World 旗下品牌包括漢庭酒店、全季酒店、桔子酒店、Steigenberger 酒店及度假村、MAXX、Jaz in the City、城際飯店、Zleep Hotels 和 Steigenberger Icons。此外，H World 還擁有美居、宜必思和宜必思尚品酒店在泛中國地區的特許經營權，以及美爵和諾富特酒店的聯合開發權。

如欲查看更多資料，請瀏覽 H World 網站：https://ir.hworld.com

無論是否出現新資料、未來事件或其他原因，除非適用法律要求，否則 H World 不承擔更新或修改任何前瞻性聲明的義務。

傳媒查詢，請聯絡：
[email protected]

Apple Inc. (AAPL.US) plans to complete price adjustments for the global iPhone 17 series before the end of August, with the price increase capped at no more than RMB1,000, Chinese media reported.

The pricing tweak could reportedly reference Apple's previous price hike plan in Japan. Previously, the top-storage version of the iPhone 17 Pro Max in Japan saw its price rise from JPY329,800 to JPY354,800, representing an increase of JPY25,000 (approximately RMB1,060).

The price of the iPhone 17 was raised to JPY142,800, up by JPY13,000 (approximately RMB551). Products including the Apple Watch Series 11, Ultra 3 and the AirPods series also saw simultaneous price increases.
~

AASTOCKS Financial News
Website: www.aastocks.com

Meta hopes to take a leading position in the open-source AI field, while Chinese tech behemoth Alibaba has once again demonstrated the intensity of market competition.

Alibaba on Monday launched an AI model that can run on consumer-grade hardware such as laptops, an area that has become a new battleground for AI model developers.

The company also opened the weights of its strongest model to maintain its leadership in open-source technology.

In announcing the new model, Alibaba said Qwen3.8-27B has outstanding capabilities in coding, professional work, research and long-horizon agent tasks.

Alibaba also said it has released the weights for its strongest model, Qwen3.8 Max, namely the calculations and rules that determine how the AI operates and behaves.

Alibaba has established a leadership position in the open-weight AI field, while other Chinese companies such as DeepSeek and Moonshot AI are also major participants.
~

AASTOCKS Financial News
Website: www.aastocks.com

SINGAPORE and SHANGHAI, Aug. 17, 2026 /PRNewswire/ -- H World Group Limited ("H World" or the "Group") (NASDAQ: HTHT; HKEX: 1179), one of the world's leading hotel groups, today announced its unaudited financial results for the second quarter of 2026, delivering strong profitability, continued improvement in its asset-light business and another quarter of solid execution.

As of June 30, 2026, the Group operated 13,539 hotels or 1,335,445 hotel rooms, with a pipeline of 3,089 hotels.

For the quarter, hotel GMV reached RMB 30.5 billion, representing an increase of 13.2% year-on-year. 

Jin Hui, CEO of H World commented: "During the second quarter, we delivered another quarter of RevPAR expansion. Our blended H World China ADR rose 2.6% year-on-year, fueling a 1.1% year-over-year lift in blended RevPAR. This performance was underpinned by ongoing product upgrades and a suite of revenue-management optimization initiatives. Meanwhile, our hotel network kept expanding at a solid pace, with 498 newly-opened hotels across China; and the number of hotels in our pipeline grew both year-over-year and quarter-over quarter. We remain firmly on track to hit our full‐ year gross opening guidance of 2,200 ‐ 2,300 hotels."

Strong Financial Performance

H World delivered a strong financial performance during the second quarter, with revenue increasing 10.8% year-over-year to RMB7.1 billion. Total adjusted EBITDA increased 20.0% year-on-year to RMB 2.7 billion.

Manachised and franchised ("M&F") revenue increased 25.2% year-over-year to RMB3.6 billion over the same period last year. Gross operating profit from the M&F business increased 18.5% to RMB 2.2 billion, reflecting continued progress of the Group's asset-light operating strategy.

Accelerating Shareholder Returns

The Group has completed ahead of schedule the US$2 billion shareholder return plan announced in 2024, underscoring the strength of its cash generation and balance sheet.

Building on this progress, the Board has approved a new three-year shareholder return plan with an aggregate amount of US$ 2.5 billion effective from August 17, 2026, through cash dividends and share repurchases.

Looking ahead, H World will remain focused on delivering 'brand-led' high-quality hotel network expansion, backed by its H Rewards membership program, technology development, and further driving operational efficiency.

For the full-year of 2026, H World raised its guidance of revenue growth to the range of 4%-8%.

For the full release please visit: 

https://ir.hworld.com/news-releases/news-release-details/h-world-group-limited-reports-second-quarter-and-interim-2026 

About H World Group Limited

Originated in China, H World Group Limited (NASDAQ: HTHT; HKEX: 01179) is a key player in the global hotel industry. Over the past 20 years, H World has developed into a leading hospitality group with a presence across diverse market segments, from economy to upper-midscale and lifestyle hotels. H World's brands include HanTing Hotel, JI Hotel, Orange Hotel, Steigenberger Hotels & Resorts, MAXX, Jaz in the City, IntercityHotel, Zleep Hotels and Steigenberger Icons. In addition, H World holds the rights as master franchisee for Mercure, Ibis and Ibis Styles, and co-development rights for Grand Mercure and Novotel in the pan-China region.

For more information, please visit H World's website: https://ir.hworld.com 

H World undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by applicable law.

For media inquiry, please contact:
[email protected] 

CHENGDU, China, Aug. 17, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", Stock Code: 6990.HK) announces its unaudited consolidated results for the period ended 30 June 2026 (the "Reporting Period").

Key information is as follows:

• Revenue amounted to approximately RMB 978 million, with sales of pharmaceutical products reaching RMB 657 million, up by 112% compared to the same period last year, driven by two factors: expert recognition of high quality clinical data and shift in treatment paradigms, and comprehensive enhancement of drug accessibility.
• The Company has established a comprehensive operational system in China encompassing R&D, manufacturing, quality management, and commercialization, with integrated drug development capabilities. The Company is also pursuing global expansion through international collaborations, leveraging external partnerships to accumulate global clinical development and commercialization experience, while exploring diversified pathways to progressively achieve independent overseas market entry.
• Focusing on ADC and novel DC, the Company not only has two ADC products that have been approved for marketing, but has also built a product pipeline that is differentiated and complimentary to approved ADCs in indications, efficacy performance and safety profile. Through the free combination of conjugation drug components, as well as the pairing with a diverse range of targeting conjugates including antibodies, small molecules, and peptides that leverage TAA/IO/ anti-angiogenetic-based mechanisms, the Company has proactively positioned innovative DC assets, including single-payload DCs such as radioisotope-based/ immuno-agonist-based/degrader-based, and dual-payload DCs such as cytotoxin + cytotoxin or immuno-agonist or degrader combinations, among others.
• Doubling down on ADC + IO therapies, including the combination of ADCs with PD-(L)1 or PD-1/VEGF agents, as well as the development of drug candidates with synergetic MoAs within one ADC compound.
• Beyond oncology, the Company has also expanded into important therapeutic areas such as autoimmune and metabolic diseases, and is currently conducting multiple clinical studies for asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis.

Clinical development progresses efficiently, with a tiered expansion of the pipeline matrix

Focusing on high-incidence tumors such as lung cancer and breast cancer, the Company has built a well-layered clinical pipeline with significant synergistic potential, covering drug modalities including ADCs, immunotherapies, and small-molecule targeted therapies, while further expanding into major therapeutic areas such as autoimmune and metabolic diseases.

Approved ADC Products

Sac-TMT (TROP2 ADC, sacituzumab tirumotecan) (also known as SKB264/MK-2870) (佳泰莱^®)
The product has currently received marketing approval for four indications, namely 2L+ TNBC, 2L/3L EGFR-mutant NSCLC, and 2L+ HR+/HER2- BC. In addition, two new indication drug applications have been accepted for review, covering the combination with pembrolizumab for 1L PD-L1-positive NSCLC, and as a monotherapy for 1L TNBC.

Clinical progress in the reporting period:

• Marketing approval for 2L+ HR+/HER2- BC
• New indication drug applications accepted for 1L TNBC and 1L PD-L1-positive NSCLC
• The OptiTROP-Lung06 registrational trial in China for 1L PD-L1-negative non-squamous NSCLC met primary endpoint
• The global Phase 3 TroFuse-005 trial for 2L+ EC met primary endpoints
• Two global Phase 3 trials for OC & UC initiated in H1 2026
• Phase 2 study in combination with SKB118 for NSCLC initiated
• Granted BTD for 1L PD-L1-positive NSCLC from NMPA

Drawing on all the aforementioned key advances, sac‑TMT has clearly embodied four core development strategies: advancing from monotherapy to combo-therapy, shifting from later-line to earlier-line treatment settings, expanding indications, and conducting clinical research from China to the global.

Trastuzumab botidotin (HER2 ADC, also known as A166) (舒泰莱^®)
One indication has received marketing approval for the treatment of 2L+ HER2+ BC. Its Phase 2 clinical study in HER2+ BC patients previously treated with topoisomerase inhibitor ADCs is ongoing.

Other ADC and novel DC assets

The Company has also built a pipeline of innovative assets that are differentiated from and complementary to approved ADCs in indications, efficacy and safety profile, including SKB315 (CLDN18.2 ADC), SKB410 (Nectin-4 ADC), SKB571 (novel bsADC), SKB107 (RDC), SKB103 (TAA-IO bsADC), and SKB565 (novel dual-payload ADC), among others.

Non-DC Assets

Clinical progress in the reporting period:
SKB118/CR-001 (PD-1/VEGF bsAb): The IND application for the treatment of solid tumors has been approved by the NMPA, and a Phase 1/2 clinical trial is ongoing.
SKB378/WIN378 (TSLP mAb): A Phase 1 clinical trial in healthy subjects has been completed in China, and its IND application for the treatment of COPD has also been approved by the NMPA.
SKB575 (TSLP/undisclosed target bsAb): Phase 1 clinical trials for atopic dermatitis and asthma are ongoing in China.

Major Key Research Findings Presented at International Academic Conferences & Journals

• The Phase 3 trial evaluating sac-TMT plus pembrolizumab versus pembrolizumab monotherapy for first-line treatment of PD-L1-positive advanced NSCLC was delivered as an oral presentation at ASCO 2026 and concurrently published in The Lancet. Compared with single-agent immunotherapy, this combination regimen yielded a significant prolongation in PFS (HR = 0.35), with consistent PFS benefits observed across all predefined subgroups; an OS benefit trend was also observed (HR = 0.55).
• The final OS analysis results from the pivotal study of sac-TMT for 3L EGFR-mutant NSCLC were selected as a LBA at ELCC 2026 and presented as a mini oral presentation.
• Lunbotinib Fumarate Capsules (RET inhibitor, also known as A400/EP0031) (宁泰莱^®[1]): Key Phase 2 clinical results for advanced RET fusion-positive NSCLC were presented in an oral presentation at ASCO 2026.

Multiple products gain market traction, with robust commercial growth momentum

To date, the Company has received marketing authorization for sac-TMT (佳泰莱^®), tagitanlimab (科泰莱^®), Cetuximab N01 (达泰莱^®) and trastuzumab botidotin (舒泰莱^®), of which 3 products covering 5 indications have been included in the National Reimbursement Drug List (NRDL). The Company has also submitted an NDA for Lunbotinib Fumarate Capsules, and upon regulatory communication and marketing approval, commercialization is expected to commence in the first half of 2027. With this, the Company's initial commercial product portfolio, comprising 5 products, has taken shape.

In the first half of 2026, the total revenue from sales of pharmaceutical products reaching RMB 657 million, up by 112% compared to the same period last year.

Major growth drivers:

Expert Recognition of High‑Quality Clinical Data and Shift in Treatment Paradigms:

• Data from a number of high‑quality clinical studies of international caliber have continued to be released, thereby continuously reinforcing the evidence-based clinical foundation of our products.
• Recognized through authoritative endorsement from clinical guideline experts, as reflected in guidelines (CSCO, etc.) and clinical expert consensus.
• 佳泰莱^® is recognized as the "standard of care in 2L and the preferred regimen in 3L" in the LC, and is also the preferred brand among TROP2 ADC in TNBC.
• Through ongoing medical education and academic exchange activities, clinicians have gained a deeper understanding of the products. Treatment paradigms have also evolved gradually.

Comprehensive Enhancement of Drug Accessibility

• Effective translation of the benefits of NRDL inclusion: 3 indications of 佳泰莱^® and 达泰莱^® have been included in the 2025 NRDL, which officially took effect on January 1, 2026. This marks 佳泰莱^® the only TROP2 ADC and the only domestic ADC in TNBC/NSCLC under the NRDL
• Broader hospital access channels: Covers 30 provinces, over 300 prefectures and over 2,000 hospitals; Broaden reimbursement channels, including formal access, temporary procurement and dual-channel reimbursement;
• Continuous expansion of the commercialization team: Established a team of 800+; nearly doubling YoY; Achieved extensive grassroots coverage of top-tier hospitals in high-potential districts

Sac-TMT (佳泰莱^®) achieved positive results in its first global Phase 3 trial, accelerating global collaboration progress

• Collaboration with Merck Sharp & Dohme (hereinafter referred to as the "MSD") (默沙东): MSD has initiated 17 ongoing Phase 3 global clinical studies of sac-TMT as a monotherapy or in combination with pembrolizumab or other agents for several types of cancer, with indications covering breast cancer (BC), lung cancer (LC), gynecologic cancers, gastrointestinal (GI) cancers, and genitourinary (GU) cancers.
  In May 2026, MSD announced that the pivotal Phase 3 Trofuse-005 trial met its primary endpoints of OS and PFS in certain patients with advanced or recurrent EC. TroFuse-005 is the first global Phase 3 trial to demonstrate statistically significant improvement in both OS and PFS compared to chemotherapy for these patients, and sac-TMT is the first and only ADC to do so for patients with EC in this setting.
  Beyond sac‑TMT, the Company has also entered into collaborations with MSD on certain ADC assets, continuously exploring the optimal ADC pipeline portfolio.
• Collaboration with Ellipses Pharma: Lunbotinib Fumarate Capsules (A400/EP0031) have received FDA approval to proceed into Phase 2 clinical development. A total of 42 clinical trial sites has been established in the United States, UK, Europe, and the United Arab Emirates for Lunbotinib Fumarate Capsules.
• Collaboration with Windward Bio: Windward Bio is evaluating SKB378/WIN378 in the POLARIS Phase 2/3 global trial in patients with asthma and has dosed the first patients in the SIRIUS Phase 2 global study in patients with COPD.
• Collaboration with Crescent Biopharma: Entered into a licensing collaboration with Crescent Biopharma for SKB105/CR-003.

ESG capabilities continue to strengthen, delivering outstanding results in capital market performance.

In terms of ESG, in May 2026, the Company was included in the "China ESG Impact List" by Fortune and was awarded bronze medal for "Most Committed to ESG (China)" under "Asia's Best Company" by FinanceAsia. In March 2026, the Company had received a rating of "AA" in the MSCI ESG Rating Assessment.

In terms of capital markets, the Company was approved by the Hong Kong Stock Exchange to officially remove the "B" marker from its stock code on April 14, 2026. In addition, the Company completed the placing of H Shares in July 2026, with net proceeds from the Placing amounting to approximately HK$2,723.4 million.

Prospect

Kelun-Biotech will continue to drive innovation and strengthen its operational capabilities, steadily advancing towards becoming a world-class biopharmaceutical company. Specifically, the Company will implement the following development strategies: advancing differentiated pipelines targeting indications with significant medical needs; optimizing payload-linker strategies and novel DC designs and structures, while expanding applications in non-oncology diseases; enhancing its end-to-end drug development and commercialization capabilities; expanding its global footprint through strategic partnerships and improve our capabilities for the development, registration and commercialization of our products in ex-China market; and optimizing its operational systems with the aim of becoming a leading global biopharmaceutical company.

－End－

About Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Kelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical, which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. Kelun-Biotech focuses on major disease areas such as solid tumors, autoimmune, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. Kelun-Biotech is committed to becoming a leading global enterprise in the field of innovative drugs. At present, Kelun-Biotech has more than 30 ongoing key innovative drug projects, of which 4 projects with 8 indications have been approved for marketing, 2 projects with 3 indications are in the NDA stage and more than 10 projects are in the clinical stage. Kelun-Biotech has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects with 5 indications approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit https://en.kelun-biotech.com/.

——20家電池工廠實現碳中和，寧德時代正式啟動2035年價值鏈碳中和行動

中國寧德2026年8月17日 /美通社/ -- 8月17日，寧德時代核心運營碳中和發佈會在福建寧德舉行。公司宣佈，2025年底已實現核心運營碳中和，成為全球唯一在TWh級出貨規模下實現核心運營碳中和的電池企業。同時，公司首次系統披露面向2035年的價值鏈碳中和行動路徑。這標誌著寧德時代的碳中和實踐從企業自身走向產業生態共建。

20家工廠實現核心運營碳中和  打造行業可複製路徑

「零碳對寧德時代來說，不僅是使命，也是在實踐中形成的能力，更是巨大的發展機遇。」寧德時代董事長兼CEO曾毓群表示，公司致力於成為一家全球領先的零碳科技公司，推動全球綠色轉型和可持續發展。2023年，寧德時代發佈零碳戰略，提出2025年實現核心運營碳中和、2035年實現價值鏈碳中和。截至2025年底，公司20家電池工廠通過ISO 14068-1認證，成為零碳工廠，核心運營零碳電力使用比例達到100%。

核心運營碳中和，是指企業自身生產運營環節實現碳排放淨零，這部分排放主要來自工廠的電力與熱能消耗，製造規模越大，實現難度越高。2025年，寧德時代生產電池748GWh；2022年至2025年，公司鋰離子電池銷量翻了2.3倍，市場份額持續保持全球第一。在高速增長的同時，寧德時代在大規模製造體系中驗證了一條可複製、具有經濟性的零碳製造路徑。

鋰電行業碳中和沒有成熟案例和權威標準可循。寧德時代從摸清碳排放來源入手，對近40道電池生產工序及上游各類物料逐一調研、梳理數據，在2022年上線「時代碳鏈」碳管理工具。目前，「時代碳鏈」已覆蓋電池生產環節及上游核心供應商，累計形成超過1000項產品和原材料模型，形成清晰的降碳路徑。

在數據基礎上，寧德時代成立零碳設計、零碳製造、零碳工廠、零碳供應、循環生態、零碳電力等六大專項推進降碳，數據顯示，2023年以來，寧德時代累計使用零碳電力超180億千瓦時，核心運營零碳電力比例達100%；2025年電池生產基地單位產品能耗較2022年下降28%，碳排放強度兩年下降約77%，累計降碳超1000萬噸二氧化碳當量。

寧德時代副總經理、董事會秘書、可持續發展委員會主任蔣理表示，公司正將零碳工廠建設中形成的方法、數據和技術經驗進一步沉澱，推動零碳從單個企業實踐轉化為行業可複製的路徑。

直面供應鏈80%的碳排放 披露2035價值鏈碳中和行動路徑

完成核心運營碳中和後，下一階段，寧德時代的目標是到2035年，實現從礦產資源到電池成品的價值鏈碳中和。目前，寧德時代產品全生命週期超過80%的碳排放來自供應鏈環節，供應鏈碳排放總量超過核心運營的5倍。僅靠一家企業無法完成，碳中和必須走向全產業鏈協同。

為此，寧德時代依托「時代碳鏈」，率先構建鋰電行業首個覆蓋「礦產開採—原料精煉—材料合成—部件製造」的全鏈路碳數據追溯平台，實現跨地域、跨環節的穿透式、可追溯管理。目前，平台已完成超100家核心一級供應商碳實景數據核算。在此基礎上，公司圍繞原材料研發、原材料生產、物流運輸、回收四大環節，制定了減碳行動計劃。

「減碳同時降本，讓綠色轉型成為經濟競爭力。『寧德時代採購中心部長黃斌表示，公司將發佈《綠色採購指南》，把碳足跡、可再生能源比例、單位產品能耗等納入供應商准入和審核，並啟動零碳供應鏈賦能計劃，首批與30家核心供應商開展深度協同減碳。同時，公司倡議成立』全球鋰電池產業零碳生態協同平台」，推動標準共建、技術協同和產業鏈聯合行動。

當天，寧德時代還與正極、負極、集流體等環節供應商共同啟動2035價值鏈碳中和行動，並與國家應對氣候變化戰略研究和國際合作中心、上海環境能源交易所達成戰略合作。

發佈會上，多位與會嘉賓從能源轉型、全球規則和市場機制等角度討論了零碳轉型。中國工程院院士凌文認為，技術創新與全球合作是突破碳中和現實挑戰的重要方向。

曾毓群表示，零碳經濟已成為新的增長方式，正在打開廣闊的產業和發展機會。今年6月，寧德時代零碳科技有限公司在廈門成立，面向全球統籌零碳技術和業務落地。寧德時代願與全球夥伴一起，把零碳能力延伸到產業鏈和更多場景，共同做大零碳經濟，共享發展新機遇。

NINGDE, China, Aug. 17, 2026 /PRNewswire/ -- CATL today announced it had achieved its 2025 target of carbon neutrality across core operations as scheduled, with all 20 battery plants certified as carbon neutral, and unveiled its action roadmap toward full value-chain carbon neutrality by 2035. This signals that decarbonization has evolved from a corporate social responsibility to a core growth driver for CATL.

At a launch event held in Ningde on Monday, the company also called on global partners to accelerate decarbonization across the battery value chain. It announced procurement guidelines that require suppliers to provide carbon footprint data from 2027, and offers favorable terms to suppliers with better carbon emission performance.

"Before contributing to global carbon rules and standards, CATL must first prove what is possible through our own industrial practice," said Robin Zeng, Chairman and CEO of CATL. "As the world ramps up efforts toward net-zero, zero-carbon batteries will not be a choice but a necessity in the near future. We are ready to share our technologies and experience with partners across the industry, helping to shape global carbon standards and advance industry-wide decarbonization."

2025 Carbon Neutrality Target for Core Operations Delivered as Planned

Since the commissioning of our first battery factory in 2012, CATL has been exploring and validating every aspect of zero-carbon manufacturing. This has become an integral part of CATL. 

Jiang Li, Vice President, Board Secretary and Head of Corporate Sustainable Development Management Committee of CATL, said, "Carbon neutrality cannot be built on estimates alone. It requires reliable data, clear boundaries and systematic execution."

To build this data foundation, CATL independently developed the CATL Carbon Chain Management System (CCMS) in 2022 to monitor and calculate carbon emissions at its plants and production lines. To date, CATL CCMS has covered carbon data across battery production operations and core upstream suppliers, generating more than 1,000 product and raw material models.

Based on this data system, CATL embeds decarbonization efforts across process and equipment optimization, battery design, green energy consumption, raw‑material sourcing and recycling.

In 2025, zero-carbon electricity accounted for 100% of electricity consumption in its core operations, with more than 18 billion kWh of zero-carbon power consumed cumulatively since 2023. Energy consumption per unit of product at its battery manufacturing bases decreased by 28% compared with 2022, below the industry average. Its carbon emission intensity decreased by approximately 77% compared with 2022. From 2023 to 2025, CATL delivered a cumulative carbon reduction of over 10 million tons of CO₂ equivalent, comparable to Brunei's total national carbon emissions in 2025.

The milestone not only marks CATL's first fulfilled carbon neutrality commitment, but also sets a new benchmark for carbon neutrality practices in the lithium-ion battery industry.

Advancing Toward Full Value-Chain Carbon Neutrality by 2035

More than 80% of carbon emissions across CATL's product lifecycle stem from its supply chain, with total value-chain emissions exceeding five times those generated in core operations.

Bryan Huang, Head of Procurement Center at CATL, said: "CATL will advance value-chain decarbonization across key areas including material innovation, material manufacturing, green logistics, and battery recycling. This requires collaboration across the entire battery value chain."

In terms of data management, baseline carbon data has been established for more than 100 core Tier 1 suppliers, and CATL aims to progressively achieve 100% data coverage across key upstream links.

For emissions reductions, CATL will pursue decarbonization in four pillars: material and process innovation, manufacturing, green logistics and battery recycling.

• Material innovation: CATL is focusing on green material innovation and low-carbon process upgrades. For example, for anodes, the company is promoting the adoption of low‑carbon materials such as raw petroleum coke with lower moisture and volatile content.
• Material manufacturing: Given the energy-intensive nature of upstream raw material production, CATL has launched a green power coverage plan, targeting 100% green electricity usage across the value chain by 2035.
• Green logistics: Leveraging its advanced battery technology and battery swapping network, CATL is promoting 100% zero-carbon logistics solutions across the industry chain.
• Battery Recycling: CATL will continue to accelerate the development of a global battery recycling network through Brunp Recycling.

To support supplier decarbonization, CATL will issue its Green Procurement Guidelines requiring new suppliers to provide product carbon footprint data and incorporating renewable electricity usage and energy efficiency into annual supplier reviews. Under comparable conditions, suppliers with stronger low-carbon performance may be prioritized in order allocation and supported through long-term agreements.

CATL will also launch its Zero-Carbon Supply Chain Empowerment Initiative, launching in-depth joint decarbonization initiatives with an initial cohort of 30 core suppliers.

The economics of zero-carbon opens substantial new growth opportunities. CATL is making strong efforts in zero-carbon mobility, zero-carbon power, and the electrification of industries, with several application scenarios already implemented. Together with global partners, CATL aims to expand the zero-carbon economy, accelerate the global clean energy transition, and help create a more sustainable future.